Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  pazopanib hydrochloride
Find trials that include:  Any drugs shown
Results 1-25 of 25 for your search:
Start Over
Radiation Therapy with or without Combination Chemotherapy or Pazopanib Hydrochloride before Surgery in Treating Patients with Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 and over
Trial IDs: ARST1321, NCI-2014-01340, NCT02180867
Pazopanib Hydrochloride in Treating Patients with Metastatic Kidney Cancer Who Have No Evidence of Disease after Surgery
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: E2810, NCI-2012-00723, CDR0000730383, ECOG-E2810, NCT01575548
A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA
Status: Active
Phase: Phase III
Type: Treatment
Age: 12 and over
Trial IDs: 105SAR301, NCI-2017-00569, NCT02979899
Temozolomide and Pazopanib Hydrochloride in Treating Patients with Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 11I03, NCI-2011-02939, NCT01465659
Pazopanib Hydrochloride and Bevacizumab in Treating Patients with Previously Untreated Metastatic Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 191711, NCI-2012-01247, 13-069, NCT01684397
A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105SAR101, NCI-2014-00305, NCT01975519
Sapanisertib or Pazopanib Hydrochloride in Treating Patients with Locally Advanced or Metastatic Sarcoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A091304, NCI-2015-01929, NCT02601209
Pazopanib Hydrochloride or Temsirolimus in Treating Patients with Metastatic or Locally Advanced Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0358, NCI-2011-01277, NCT01392183
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: OER-SAR-043, NCI-2011-01314, IRB#11-042, NCT01462630
Pazopanib Hydrochloride and Anastrozole or Letrozole in Treating Patients With Advanced Hormone-Resistant Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117513, NCI-2012-00494, NCT01466972
Gemcitabine Hydrochloride with or without Pazopanib Hydrochloride in Treating Patients with Refractory Soft Tissue Sarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 and over
Trial IDs: 7943, NCI-2012-00052, NCT01532687
Gemcitabine Hydrochloride and Docetaxel or Pazopanib Hydrochloride in Treating Patients with Metastatic, Locally Advanced, or Locally Recurrent Soft Tissue Sarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 90
Trial IDs: 101644, NCI-2012-00675, CPZP034BUS1T, CPZP034BUS21T, MUSC 101644, PAZ115785, PZP115785, NCT01593748
Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16153, NCI-2013-00494, GEM-PAZ-2012, OVA-7, NCT01610206
Pazopanib Hydrochloride in Treating Patients with Metastatic Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC1152, NCI-2012-02027, NCT01767636
Pazopanib Hydrochloride Followed by Surgery in Treating Patients with High-Risk Prostate Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI63129, NCI-2014-00453, 63129, PZP116921, NCT01832259
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients with Recurrent Glioblastoma Multiforme
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0034, NCI-2015-00601, BTTC12-01, NCI-2014-00490, P152463, NCT01931098
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 18
Trial IDs: 116731, NCI-2015-00058, NCT01956669
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients with Locally Advanced or Metastatic Soft Tissue and Bone Sarcomas That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14S03, NCI-2014-02583, STU00200112, NCT02357810
Pazopanib Hydrochloride and Everolimus in Treating Patients with Advanced Solid Tumors or Previously Treated Advanced Urothelial Cancer
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-166, NCI-2011-00034, NCT01184326
Pazopanib Hydrochloride and Abexinostat in Treating Patients with Metastatic Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11955, NCI-2012-01142, UCSF Protocol No. 11955, NCT01543763
Pazopanib Hydrochloride in Treating Molecularly Selected Patients with Advanced Non-small Cell Lung Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201408009, NCI-2014-01760, 201566, PRMC 14-X182, NCT02193152
HDAC Inhibitor AR-42 and Pazopanib Hydrochloride in Treating Patients with Advanced Soft Tissue or Kidney Cancer
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-14-10774, NCI-2016-00851, NCT02795819
Dynamic Contrast-Enhanced MRI and Ultrasound in Measuring Tumor Perfusion Changes in Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery Receiving Pazopanib Hydrochloride
Status: Active
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: UPCC 34809, NCI-2012-00754, NCT01221506
Pazopanib Hydrochloride with Low Fat Meal in Treating Patients with Locally Advanced or Metastatic Kidney Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: UMCC 2016.013, NCI-2016-00458, NCT02729194
Start Over